EXCELSIOR PHARMATECH LABS.

Excelsior group has been dedicated to specialty medicines and medical examinations in rare diseases for more than 2 decades. In 2016, Excelsior group established a TGF-beta research center and start up new drug development projects to screen new drug candidates of enhancers and inhibitors targeting at TGF-beta activities in various diseases, such as wound healing, cardiovascular diseases, autoimmune diseases, liver cirrhosis, pulmonary fibrosis, neurodegenerative diseases, and cancer treatments. In 2020, Excelsior group is expanding our team in the field of rare diseases and establish a new research center of specific diseases aim at genetic and metabolic disorders in National Biotechnology Research Park, NBRP. In NBRP, we are investing in precision medical testing, epidemiology study, new drug development, and novel therapeutic technologies in various rare diseases. Besides, we are also looking for more strategic alliances with Academia Sinica, National Health Research Institute and leading medical centers in Taiwan. Our aim is to establish a world-class laboratories in the research of TGF-beta and specific diseases and extend our services to Asian populations.

Feng Chi Biotech corp.

accurate medication with diagnosis

1. Biomarker diagnosis of cancer and target therapy
 Lung cancer EGFR mutation detection (tissue, liquid biopsy)
 Colorectal cancer All RAS mutation detection (tissue)
 Breast cancer PIK3CA mutation detection (tissue)
 Comprehensive detection of gene fusion target drug group (organization)
 Comprehensive detection of blood cancer gene fusion and mutation
 Sarcoma genome testing
 Highly sensitive detection of minimal residual disease in tumor liquid biopsy

2. Antibiotic resistance diagnosis
 NG-Test MCR-1: NG-Test MCR-1 is a qualitative rapid immunoassay for the detection of the MCR-1 enzyme in a bacterial colony obtained from culture.
 NG-Test CARBA 5: an in vitro rapid and visual multiplex immunochromatographic assay for the qualitative detection and differentiation of five common carbapenemases (KPC, OXA-48-like, VIM, IMP and NDM) from carbapenem non-susceptible pure bacterial colonies.
 NG-Test CTX-M MULTI: NG-Test CTX-M MULTI is a qualitative rapid immunoassay for the detection of CTX-M groups 1, 2, 8, 9 and 25 in a bacterial colony obtained from culture.

Fooyin University/Aging and Disease Prevention Research Center

According to the demand of precision health industry, the center has integrated the research and development energy of the school, built the intestinal precision medical platform, commercial microbacterial phase analysis platform, personalized gene testing platform, health food efficacy verification platform, probiotic enzyme platform and animal experimental platform, to provide technical services for the production and medical community.In addition, through direct cooperation with affiliated hospitals, we have launched intestinal bacteria detection kits, fast intestinal bacteria screening products, QPCR single strain detection and disease genetic testing products. At present, we have signed contracts with 12 medical and health examination companies to assist their intestinal tracts. Health and disease detection, and gradually develop industrial health innovation services and products, promote Taiwan's intestinal precision medical industry, and hope to achieve the goal of mutual benefit between industry and academia, and improve the health of the whole people.

Franz Biotech Inc

Franz Inc./Franz Biotech Inc. is the global leader in ceramic 3D printing technologies and provides additive solutions to help customers to manufacture various electronic components with light, thin and short in size. Their application fields cover medical devices, semiconductors, information and communication technology products, and other emerging products. With our 3D-print services, we can assist many industries in the development of customized electronics, such as nanosatellites, 5G/6G mobile phone antennas, machined components, and electronics products, which help to optimize traditional manufacturing procedures. Here, as compared with other ceramic 3D printing technologies, the most unique feature of our creative 3D printing fabrication is that it can print extremely fine models without any support structures. For details, please refer to https://3d.franzcollection.com.tw/
Recently, we have also achieved success in the development of medical device. In 2020, the "3D printed all-ceramic crown" was officially proved by the TFDA. It is the only one that has passed the TFDA certification. Besides, the USA FDA certification is expected to pass by Q1, 2022. In 2021, Franz Inc./Franz Biotech Inc. cooperates with the NYCU interdisciplinary team of Memory Engrams Research (funded by Taiwan Brain Technology Development and International Raising Program, Ministry of Science and Technology) to develop a next generation of ceramic 3D-printed neural chip, which can be used for preclinical studies in diagnosis and treatment of neurodegenerative diseases. We are expected to promote ceramic 3D printing technology to the market of clinical medical devices in the future.

General Biologicals Corporation

CellBio™ provides essential functions required to transform resource-heavy manual Circulating Tumor Cell (CTC) detection into an automated, high-throughput, high-capacity process that is suited to clinical practice within less than 90 minutes.
With more than 1,000 samples testing, the system offers more than 90% capture rate. Recently Fubon Insurance Company in Taiwan has selected patented CellBio™ solution for their insurance policy holders to screen for cancers.

GeneReach Biotechnology Corporation

The bench-top POCKIT® Central Nucleic Acid Analyzer(POCKIT® Central) integrates magnetic bead-based nucleic acid extraction as well as fluorescence-based insulated isothermal PCR (iiPCR), signal detection, and data processing/interpretation. POCKIT® Central offers a simple sample-in-answer- out protocol for up to 8 samples within 85 minutes. Complicated operation procedures and human operation errors are minimized.

Genetech Biotech

Genomic sequencing and cell biology related products

Genomics BioSci. & Tech. Co., Ltd.

Non-Invasive Prenatal Testing (NIPT)
NIPT can analysis chromosomal aneuploidy and the major diseases is three copies of chromosome, Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome) and Trisomy 13 (Patau syndrome).

Spinal muscular atrophy (SMA) Carrier Screening
Spinal muscular atrophy (SMA) is an autosomal recessive disease that causes progressive muscle wasting and weakness due to loss of motor neurons in the spinal cord. The disease is often fatal and is the leading genetic cause of death in infants. SMA incidence is approximately 1 in 10,000 live births and the carrier rate is 1 in 50.

Fragile X Syndrome Premutation Screening
Genetic analysis is the preferred method of diagnosis for fragile X syndrome. Prenatal testing for fragile X syndrome should be offered to known carriers of the fragile X premutation or full mutation.

Gwo Xi Stem Cell Applied Technology Co., Ltd.

GWOXI Stem Cell R&D Center was established in 2011 and committed to developing the potential stem cell therapies that satisfy the unmet medical needs and further contribute to the medical field. The production platform is fully compliant with medical regulations (Good Tissue Practice, GTP) in Taiwan. We have three clinical trials are going in Taiwan by now including GXHPC1, GXNPC1, and GXCPC1, indications of liver cirrhosis, stroke, and osteoarthritis, respectively. In addition, we currently also have a clinical trial, GXIPC1 is going in Vietnam, which is applied for type I diabetes executed in Vinmec Research Institute of Stem Cell and Gene Technology (VIRISG). Four clinical trials are using adipose-derived stem cells (ADSCs) as cell sources, and the administrations are local transplantation instead of intravenous injection, which have great potential for improving outcomes. The safety reports related to clinical trials using stem cells are provided by our testing lab, GTESTing® lab (TAF certification number: 2800), which is with the international standard for laboratory quality system. So far, we have established R&D Center, ATMP lab, and PIC/S GMP stem cell factory for developing and manufacturing advanced cell therapy products. In the future, based on our established research capability, we will actively promote innovative stem cell products from Taiwan to the international market through collaboration with strategic partners of the alliance.

Gwo Xi Stem Cell Applied Technology Co., Ltd.

GWOXI Stem Cell R&D Center was established in 2011, and committed to developing the potential stem cell therapies that satisfy the unmet medical needs and further contribute to the medical field. The production platform is fully compliant with medical regulations (Good Tissue Practice, GTP) in Taiwan. We have three clinical trials are going in Taiwan by now including GXHPC1, GXNPC1 and GXCPC1, indications of liver cirrhosis, stroke and osteoarthritis, respectively. In addition, we currently also have a clinical trial, GXIPC1, is going in Vietnam, which is applied for type I diabetes executed in Vinmec Research Institute of Stem Cell and Gene Technology (VIRISG). Four clinical trials are using adipose-derived stem cells (ADSCs) as cell source, and the administrations are local transplantation instead of intravenous injection, which have the great potential for improving outcomes. The safety reports related to clinical trials using stem cell are provided by our testing lab, GTESTing® lab (TAF certification number: 2800), which is with international standard for laboratory quality system. So far, we have established R&D Center, ATMP lab and PIC/S GMP stem cell factory for developing and manufacturing the advanced cell therapy products. In the future, based on our established research capability, we will actively promote innovative stem cell products from Taiwan to international market through collaborating with strategic partners of the alliance.